Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 2/2012

01-02-2012 | Original Article

Managing chronic pain: results from an open-label study using MC5-A Calmare® device

Authors: Marianna Ricci, Sara Pirotti, Emanuela Scarpi, Marco Burgio, Marco Maltoni, Elisabetta Sansoni, Dino Amadori

Published in: Supportive Care in Cancer | Issue 2/2012

Login to get access

Abstract

Background

Despite state-of-the-art therapeutic strategies for pain, some types of chronic pain remain difficult to treat. We evaluated the effectiveness of an innovative neuromodulative approach to the treatment of chronic pain using electrical stimulus integrated with pharmacological support.

Methods

The MC5-A Calmare© is a new device for patient-specific cutaneous electrostimulation which, by “scrambling” pain information with “no pain” information, aims to reduce the perception of pain intensity. We prospectively treated 73 patients with cancer- (40) and non-cancer-related (33) pain whose pain management was unsatisfactory. The primary objective of the study was to assess efficacy and tolerability of the device. Pain intensity was assessed daily with a Numerical Rating Scale (NRS) for the duration of treatment (2 weeks) and then on a weekly basis for the 2 weeks of follow-up.

Results

Mean pain value at T0 (pre-treatment value) was 6.2 [±2.5 SD (standard deviation)], 1.6 (±2.0) (p < 0.0001) at T2 (after the 10th day of treatment), and 2.9 (±2.6) (p < 0.0001) at T4 (after the second week of follow-up, i.e., 1 month after the beginning of treatment). Response after the second week of treatment showed a clear reduction in pain for both cancer (mean absolute delta of the reduction in NRS value = 4.0) and non-cancer (mean delta = 5.2) patients. The pain score had decreased by 74% at T2. On the basis of pre-established response criteria, there were 78% of responders at T2 and 81% at T4. No side effects were reported.

Conclusions

Our preliminary results suggest that cutaneous electrostimulation with the MC5-A Calmare© can be hypothesized as part of a multimodality approach to the treatment of chronic pain. Further studies on larger numbers of patients are needed to assess its efficacy, to quantify the effects of inter-operator variability, and to compare results obtained from the active device versus those from a sham machine.
Literature
1.
Siddall P, Cousins M (2004) Persistent pain as a disease entity: implications for clinical management. Anesth Analg 99:510–520PubMedCrossRef
2.
Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D (2006) Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 10:287–333PubMedCrossRef
3.
Breivik H, Cherny N, Collett B, de Conno F, Filbet M, Foubert AJ, Cohen R, Dow L (2009) Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Ann Oncol 20:1420–1433PubMedCrossRef
4.
Zenz M, Zenz T, Tryba M, Strumpf M (1995) Severe undertreatment of cancer pain: a 3-year survey of the German situation. J Pain Symptom Manage 10:187–191PubMedCrossRef
5.
Von Roenn J, Cleeland C, Gonin R, Hatfield A, Pandya K (1993) Physician attitudes and practice in cancer pain management. A survey from the Eastern Cooperative Oncology Group. Ann Intern Med 119:121–126
6.
Agency for Health Care Policy and Research (1994) Clinical practice guideline cancer pain management. US Department of Health and Human Services, Rockville
7.
8.
De Leon-Casasola O (2009) Spinal cord and peripheral nerve stimulation techniques for neuropathic pain. J Pain Symptom Manage 38(2S):S28–S38PubMedCrossRef
9.
American Society of Anesthesiologists Task Force on Chronic Pain Management; American Society of Regional Anesthesia and Pain Medicine (2010) Practice guidelines for chronic pain management. Anesthesiology 112:810–833
10.
Smith T, Coyne P, Parker G, Dodson P, Ramakrishnan (2010) Pilot trial of a patient-specific cutaneous electrostimulation device (MC5-A Calmare®) for chemotherapy-induced peripheral neuropathy. J Pain Symptom Manage 40(6):883–891PubMedCrossRef
11.
Foletti A, Durrer A, Buchser E (2007) Neurostimulation technology for the treatment of chronic pain: a focus on spinal cord stimulation. Expert Rev Med Devices 4:201–214PubMedCrossRef
12.
Ghoname E, Craig W, White P, Ahmed HE, Hamza MA, Henderson BN, Gajraj NM, Huber PJ, Gatchel RJ (1999) Percutaneous electrical nerve stimulation for low back pain: a randomized crossover study. JAMA 281:818–823PubMedCrossRef
13.
Harke H, Gretenkort P, Ledleif H, Rahman S (2005) Spinal cord stimulation in sympathetically maintained complex regional pain syndrome type I with severe disability. A prospective clinical trial. Eur J Pain 9:363–373PubMedCrossRef
14.
Mailis-Gagnon A, Furlan A, Sandoval J, Taylor R (2003) Spinal cord stimulation for chronic pain. Cochrane Database Syst Rev 3:CD003783
15.
Khadikar A, Milne S, Brosseau L, Robinson V, Saginur M, Shea B, Tugwell P, Wells G (2005) Transcutaneous electrical nerve stimulation (TENS) for chronic low-back pain. Cochrane Database Syst Rev 4:CD003008
16.
Robb K, Oxberry S, Bennett M, Johnson MI, Simpson KH, Searle RD (2009) A Cochrane systematic review of transcutaneous electrical nerve stimulation for cancer pain. J Pain Symptom Manage 37:746–753PubMedCrossRef
17.
Nnoaham K, Kumbang J (2008) Transcutaneous electrical nerve stimulation (TENS) for chronic pain. Cochrane Database Syst Rev 3:CD003222PubMed
18.
Marineo G (2003) Untreatable pain resulting from abdominal cancer: new hope from biophysics? JOP 4:1–10PubMed
19.
Sabato AF, Marineo G, Gatti A (2005) Scrambler therapy. Minerva Anestesiol 71:479–482PubMed
20.
Gatti A, Sabato AF, Marineo G (2007) Scrambler therapy in neuropathic pain. Pathos 14:99–105
21.
Caraceni A, Cherny N, Fainsinger R, Kaasa S, Poulain P, Radbruch L, De Conno F (2002) Pain measurement tools and methods in clinical research in palliative care: recommendations of an expert working group of European Association of Palliative Care. J Pain Symptom Manage 23:239–255PubMedCrossRef
22.
De Conno F, Caraceni A, Gamba A, Mariani L, Abbattista A, Brunelli C, La Mura A, Ventafridda V (1994) Pain measurements in cancer patients: a comparison of six methods. Pain 57:161–166PubMedCrossRef
23.
Caraceni A, Mendoza TR, Mencaglia E, Baratella C, Edwards K, Forjaz MJ, Martini C, Serlin RC, de Conno F, Cleeland CS (1996) A validation study of an Italian version of the Brief Pain Inventory (Breve Questionario per la Valutazione del Dolore). Pain 65:87–92PubMedCrossRef
24.
Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS (1995) When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 61:277–284PubMedCrossRef
25.
26.
Mercadante S (2006) Pathophysiology of chronic pain. In: Bruera E, Higginson IJ, Ripamonti C, von Gunten C (eds) Textbook of palliative medicine. Hodder Arnold, London, pp 359–366
27.
Ricci M, Pirotti S, Burgio M, Scarpi E, Sansoni E, Ridolfi R, Amadori D, Maltoni M (2010) Safety and efficacy of scrambler therapy for cancer pain. J Clin Oncol 28 (suppl; abstr e19591)
Metadata
Title
Managing chronic pain: results from an open-label study using MC5-A Calmare® device
Authors
Marianna Ricci
Sara Pirotti
Emanuela Scarpi
Marco Burgio
Marco Maltoni
Elisabetta Sansoni
Dino Amadori
Publication date
01-02-2012
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 2/2012
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-011-1128-6

Other articles of this Issue 2/2012

Supportive Care in Cancer 2/2012 Go to the issue

Original Article

Pneumatosis intestinalis in children with acute lymphoblastic leukemia and acute myeloid leukemia

Short Communication

Hispanic adolescents coping with parental cancer

Original Article

Weight loss in cancer patients: a plea for a better awareness of the issue

Original Article

Association of oral mucositis with quality of life and symptom clusters in patients with solid tumors receiving chemotherapy

Original Article

Defining treatment for brain metastases patients: nihilism versus optimism

Short Communication

Unmet needs and distress in people with inoperable lung cancer at the commencement of treatment
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits